Episurf Medical announced that the company's 510(k) application to the US FDA for market clearance for the Episealer® Patellofemoral System now is progressing to the substantive review phase.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.368 SEK | -7.65% | -48.10% | -62.83% |
Apr. 24 | Episurf Medical AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 22 | Episurf Medical Plans SEK120 Million Rights Issue | MT |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-62.83% | 9.03M | |
+12.59% | 128B | |
-10.58% | 10.51B | |
-0.39% | 8.71B | |
+13.56% | 7B | |
+25.94% | 5.02B | |
+6.93% | 3.39B | |
-1.64% | 3.02B | |
-11.96% | 2.07B | |
-7.25% | 2.06B |
- Stock Market
- Equities
- EPIS B Stock
- News Episurf Medical AB
- Episurf Medical Provides Updates of 510(K) Application on Episealer Patellofemoral System